`L UCENT!S
`
`8usinffs Use Only
`
`Lucentis PFS (RFB002)
`
`TRD SubTeam meeting
`
`M lmitesA.Ber..oo
`
`Meeting Dato: Dec. 10, 2012
`Meeting Notes Date: -Jan. 4. 20 ! '.l
`Author:
`Room: WSJ-340.3.09
`Dial-in:
`
`J!J] __
`
`4 •• ~ · ··· · · ·l.Formatted:. Centered,. Indent: .Left: .. :0.19. cm ............................ )
`
`-'·
`
`•-• 1 Formatted: Tab stops: Not at 1.27 cm
`
`4
`
`,
`
`:
`
`,
`
`· ·\,' \
`... \ \
`
`w,_,.-.., ~
`
`1
`
`...... ,·•'°'·[ Formatt<!d: Font: (Asian) Japanese
`, ,,.......,
`.,.,,,,.,
`,..,_
`,.-,,
`·.-.,
`w.
`.-.,
`i
`............ i Formatted: I ndent : Left: 0.07 cm, H<1nging ; O.S cm,
`··· '-
`, Bulleted 4 Level : I 4 Aligned at: 0.63 cm 4 Tab after: 1.27
`i
`j tm + Indent at: 1.27 cm, Tab stops: O.S7 cm, List tab + Not l
`·\'\Lat 1.27 cm
`·
`~~
`\ . 1 Formatted: Font: No underline
`· .. ~\'' \i Formiltted: Tab stops: Not at l.27 cm
`~ "- i Formatted: Font:
`l
`j
`\~ 1· Form atted: Font: (Default} Ari~I, Font color: Auto
`'1
`\; Formatted: Chai' Char Char Char Char, Indent: Laft: 0.07
`l
`cm., Hangilg: 0.5 cm, Space Before: 6 pt, Arter: 6 pt,
`6ulle\od + Level: I + Aligned at: 0.63 cm + Tab after: 1.27
`i
`·
`<.m + Jndent at: 1.27 cm, Adjust space between Latin and
`Asian text, Adjust space bet¼ieen Asian text and numbers, Tab !
`\ .,, stops: 2.32 cm, l.i$t tab + Not at 1.27 cm
`.
`<\ \ j Formatted: Font: (Default) Hetv, Font color': 81a,c:lc, (Asian)
`\ \ 1 Formatt<!d: Font: (Default) Arial
`\ . \:i Formatted: Font: (Default) Arial, F-ont color: Auto
`,>-·--------···"-"""' _______ _
`
`\ \
`
`\ i Japanese
`
`. . w
`
`... , \
`
`, \ Formatted: Font: (Def-au It) Arial, Font color: Auto
`
`~ Formatted: Font: (Default) Arial, Font color: Auto
`[ Formatt<!d: Font: (Default) Arial
`
`1 of 7
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2088.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Pre-rea<ls
`
`I
`
`Topic;/Situation
`
`I
`
`Discussion
`
`Actions
`What
`
`t opic/Situation: Sterilization
`
`-
`
`Oisc1m;ion
`
`Lead;
`
`Pre-reads
`
`................................................................................................................ ,
`......... , ... ,··: Formatted: Font: Not Italic
`l
`
`r···
`~:--.-....~:···l Formatted: Font: Itai c
`~ Formatted: Indent· Left: 1.27 cm
`
`2of 7
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2088.002
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`······ .... ·l Formatted: Normal, No bulets or numbering
`
`'
`
`...,
`
`... .
`
`. ., ,
`
`~-·
`
`w
`
`., .
`
`,,.,.,...,
`
`... .
`
`. .,,
`
`.,, ,
`
`l
`
`, ;
`
`w
`
`., .
`
`"\ , ..,.~·-· .. f Formatted: Font: ltaWc
`.
`....• ·,
`...
`'rw_M.•Nl'N'M.•NM,v ______ .,..,m,,,.·,..,mM.•NmM.•NmM.•N- - -~
`' l.~~rmatted: fndent: Left: L.27 cm
`j
`
`Actions
`What
`
`Who
`
`.I
`
`Topic/Situation: Project update
`
`Project update:
`
`Dlscussion
`
`I
`
`'Lead:
`
`Pre-reads
`
`3 of 7
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2088.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Who
`
`Wilen
`
`Lead:
`
`Pre-reads
`
`/' ............................ .
`i Field Code Cha 1111ed
`I
`
`... /
`
`Actioris
`What
`
`Topic/Situation
`
`I
`I
`I
`I
`
`Discussion
`
`-
`
`Topic/Situation: Proj ect upd ate
`
`I
`
`l uad:
`
`4 of 7
`
`CONTAINS CONFIDENTIAL BUSI NESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2088.004
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Discussion
`
`Actions
`What
`
`Topic/Sit11a1ion
`
`DiScusSl:on
`
`Actions
`What
`
`I
`I ":""w"oo
`
`,~ Field Code Changed
`
`When
`
`Who
`
`(-
`
`/ { Field Code Changed
`
`//
`I
`. .I
`
`When
`
`Lead :
`
`Pre-reads
`
`~Jc,,e
`
`I
`
`.. ~.,,.-" .... f Formatted: Font: Not Italic
`..
`
`5of 7
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2088.005
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Discussion
`
`Actions
`What
`
`Consolidated Action Plan
`
`Who
`
`Whan
`
`'-$ •
`
`• -
`
`! Formatted: Indent: Left: 0 cm
`
`6 of 7
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2088.006
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`7 of 7
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2088.007
`Regeneron v. Novartis, IPR2021-00816
`
`